{"slideshow_credits": null, "snippet": "The drug manufacturer, recipient of a $5.6 billion takeover bid, disclosed that almost 5 percent of prescriptions generated reports of ill effects.", "abstract": "Regulatory filing by drug maker Questcor, which has received a $5.6 billion takeover bid from Mallinckrodt Pharmaceuticals, discloses that nearly 5 percent of prescriptions dispensed for immune-system drug Acthar were reported to have caused serious illness; Acthar costs $28,000 per five-milliliter vial, and accounts for 95 percent of Questcor's revenue.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Gretchen", "role": "reported", "lastname": "MORGENSON", "rank": 1, "organization": ""}], "original": "By GRETCHEN MORGENSON", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/07/11/business/questcor-reveals-adverse-events-data-for-acthar-for-first-time.html", "lead_paragraph": "The drug manufacturer, recipient of a $5.6 billion takeover bid, disclosed that almost 5 percent of prescriptions generated reports of ill effects.", "headline": {"main": "Questcor Reveals Adverse Events Data for Acthar for First Time", "print_headline": "Drug\u2019s Risks Are Disclosed in a Filing"}, "_id": "53bf16ce38f0d85829e27880", "word_count": "688", "multimedia": [{"height": 126, "url": "images/2014/07/11/business/subQuestcor/subQuestcor-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/07/11/business/subQuestcor/subQuestcor-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 75, "url": "images/2014/07/11/business/subQuestcor/subQuestcor-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/07/11/business/subQuestcor/subQuestcor-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-07-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Mallinckrodt Pharmaceuticals", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Securities and Exchange Commission", "name": "organizations", "is_major": "N", "rank": "7"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "6"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "is_major": "N", "rank": "8"}, {"value": "Acthar (Drug)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Questcor Pharmaceuticals Incorporated", "name": "organizations", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}